BioNexus Gene Lab Corp (BGLC) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 22, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 14, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the BGLC SEC filings page.
BioNexus Gene Lab Corp (BGLC) reported $3.1M in revenue over the twelve months to Jun 30, 2026, down 67.3% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 8 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
The business has a thin gross-profit base, and falling sales now leave operating costs too large to absorb.
FY2025 revenue fell21.9% , yet gross margin improved to14.6% , indicating the sharper problem was below gross profit rather than product-level cost pressure. Operating cash flow of-$1.84M nearly matched free cash flow of-$1.88M , so the cash shortfall was overwhelmingly operational rather than investment-led.
Liabilities fell to
SG&A consumed
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed: here 4 of 6, with the others left out rather than counted as zero. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of BioNexus Gene Lab Corp's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Not available for BioNexus Gene Lab Corp, so it is left out of the overall score, which averages the 4 of 6 dimensions that can be computed.
BioNexus Gene Lab Corp had 2M shares outstanding at the end of fiscal year 2025. Dilution ranks emerging companies on how fast that count has grown over three years, where a slower rise is the better one, and BioNexus Gene Lab Corp scores 93/100 among other emerging companies.
BioNexus Gene Lab Corp spent $51K on research and development in fiscal year 2025, which was 0.5% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and BioNexus Gene Lab Corp scores 6/100 among other emerging companies.
BioNexus Gene Lab Corp reported revenue of $7.4M in fiscal year 2025, against $9.5M in fiscal year 2024. Revenue Progress ranks emerging companies on the three-year path of that line, and BioNexus Gene Lab Corp scores 26/100 among other emerging companies.
BioNexus Gene Lab Corp's operations used $1.8M of cash in fiscal year 2025, against $2.1M used in fiscal year 2024. Burn Trend ranks emerging companies on which way that figure has moved over three years, and BioNexus Gene Lab Corp scores 46/100 among other emerging companies.
Not available for BioNexus Gene Lab Corp, so it is left out of the overall score, which averages the 4 of 6 dimensions that can be computed.
BioNexus Gene Lab Corp scores 2.70, placing it in the grey zone between 1.81 and 2.99. The largest contribution to the score comes from a market capitalization of $3.5M against total liabilities of $638K. This signals moderate financial risk that warrants monitoring.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
BioNexus Gene Lab Corp passes 4 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 1 of 4 profitability signals pass, all 2 leverage/liquidity signals pass, 1 of 2 operating efficiency signals passes.
BioNexus Gene Lab Corp reported a net loss of $3.0M while operations used $1.8M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
BioNexus Gene Lab Corp generated $76K in revenue in Q2 2026. This represents a decrease of 96.6% from the same quarter a year earlier. Against the prior quarter it is up 233.4%.
BioNexus Gene Lab Corp's EBITDA was -$254K in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
BioNexus Gene Lab Corp reported a net loss of $286K in Q2 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
BioNexus Gene Lab Corp earned -$0.12 per diluted share (EPS) in Q2 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Cash & Balance Sheet
BioNexus Gene Lab Corp recorded an outflow of $423K in free cash flow in Q2 2026, representing a cash shortfall after capex. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
BioNexus Gene Lab Corp held $1.2M in cash as of Q2 2026; no long-term debt figure is on record for that period.
Not reported for Q2 2026.
Margins & Returns
BioNexus Gene Lab Corp's gross margin was 17.1% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is up 0.8 percentage points from the same quarter a year earlier. Against the prior quarter it is up 20.5 percentage points.
BioNexus Gene Lab Corp's quarterly ROE was -3.7% in Q2 2026: one quarter's net income over shareholder equity, not annualized. This is up 4.5 percentage points from the same quarter a year earlier. Against the prior quarter it is up 3.0 percentage points.
Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Capital Allocation
BioNexus Gene Lab Corp invested $14K in research and development in Q2 2026. This represents an increase of 8.9% from the same quarter a year earlier. Against the prior quarter it is down 5.6%.
BioNexus Gene Lab Corp invested $250 in capex in Q2 2026, funding long-term assets and infrastructure. This represents a decrease of 98.8% from the same quarter a year earlier. Against the prior quarter it is down 23.1%.
Not reported for Q2 2026.
BGLC Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $76K-96.6% | $23K-98.9% | $484K-80.8% | $2.5M-3.3% | $2.3M+14.5% | $2.1M-10.3% | $2.5M+11.0% | $2.6M+3.0% |
| Cost of Revenue | $63K-96.7% | $24K-98.7% | $488K-78.0% | $2.2M-6.0% | $1.9M+12.2% | $1.8M-11.1% | $2.2M+10.4% | $2.3M+4.8% |
| Gross Profit | $13K-96.5% | -$790-100.2% | -$4K-101.3% | $378K+15.7% | $368K+27.5% | $343K-5.9% | $309K+16.0% | $327K-7.8% |
| R&D Expenses | $14K+8.9% | $14K+19.3% | $11K-36.2% | $15K+42.5% | $13K+53.2% | $12K+5.8% | $17K | $10K |
| SG&A Expenses | $335K-70.3% | $380K-59.2% | $217K-67.2% | $997K-51.1% | $1.1M+61.8% | $933K+98.6% | $661Kn/m | $2.0M-33.9% |
| Operating Income | -$282Kn/m | -$540Kn/m | -$1.0Mn/m | -$703Kn/m | -$611K-335.9% | -$618Kn/m | -$416K-261.5% | -$1.3Mn/m |
| EBITDA | -$254Kn/m | -$512Kn/m | -$1.0Mn/m | -$674Kn/m | -$597K-305.4% | -$578Kn/m | -$373K-229.8% | -$1.3Mn/m |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $6K+45.4% |
| Income Tax | $0n/m | $0n/m | $0n/m | $0-100.0% | $0-100.0% | $0n/m | -$41Kn/m | $2K-98.0% |
| Net Income | -$286Kn/m | -$544Kn/m | -$1.0Mn/m | -$709Kn/m | -$616K-409.5% | -$623Kn/m | -$348K-212.9% | -$1.3Mn/m |
| EPS (Diluted) | -$0.12n/m | -$0.23n/m | N/A | -$0.40 | -$0.34 | -$0.35 | N/A | -$0.75 |
| Diluted Shares (Avg) | 2M+34.5% | 2M+34.5% | N/A | 2M | 2M | 2M | N/A | 2M |
Not reported in any period shown, so not listed: EPS (Basic).
BGLC Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $8.7M-7.4% | $9.0M-4.6% | $9.3M-11.3% | $7.6M-30.7% | $9.4M-15.4% | $9.5M-15.1% | $10.4M-8.5% | $11.0M-4.1% |
| Current Assets | $4.9M-22.5% | $5.2M-20.6% | $5.4M-26.7% | $5.6M-20.1% | $6.4M-18.7% | $6.5M-17.2% | $7.4M-7.7% | $7.0M-14.9% |
| Cash & Equivalents | $1.2M-19.8% | $1.3M-36.0% | $2.4M-17.4% | $1.2M-72.1% | $1.5M-71.6% | $2.1M-52.9% | $2.9M-36.1% | $4.1M-32.7% |
| Short-Term Investments | $0 | $0 | $0 | N/A | N/A | N/A | N/A | $0n/m |
| Inventory | $653K-46.3% | $667K-43.4% | $677K-51.3% | $1.0M-27.5% | $1.2M+17.7% | $1.2M+9.5% | $1.4M+22.0% | $1.4M+25.4% |
| Accounts Receivable | $16K-99.2% | $80K-94.5% | $506K-63.3% | $1.5M+6.8% | $1.9M+87.5% | $1.4M+71.8% | $1.4M+72.1% | $1.4M+58.3% |
| Long-Term Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $0n/m |
| Total Liabilities | $948K-50.1% | $947K-44.6% | $638K-69.8% | $805K-49.9% | $1.9M+19.1% | $1.7M-6.0% | $2.1M+21.2% | $1.6M-9.6% |
| Current Liabilities | $813K-53.8% | $796K-49.0% | $521K-73.3% | $678K-52.1% | $1.8M+25.6% | $1.6M-9.1% | $2.0M+19.6% | $1.4M-13.9% |
| Non-Current Liabilities | $135K-4.5% | $150K+1.7% | $117K-26.8% | $127K-33.9% | $141K-27.4% | $148K+46.8% | $160K+43.9% | $192K+43.6% |
| Total Equity | $7.8M+3.4% | $8.1M+4.1% | $8.6M+3.5% | $6.8M-27.4% | $7.5M-21.2% | $7.8M-16.8% | $8.3M-13.8% | $9.4M+0.8% |
| Retained Earnings | -$7.3Mn/m | -$7.0Mn/m | -$6.4Mn/m | -$5.4Mn/m | -$4.7Mn/m | -$4.1Mn/m | -$3.4Mn/m | -$3.1Mn/m |
Not reported in any period shown, so not listed: Goodwill, Long-Term Debt.
BGLC Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$422Kn/m | -$148Kn/m | $961K+338.4% | -$1.2Mn/m | -$738Kn/m | -$824Kn/m | $219Kn/m | -$1.6Mn/m |
| Depreciation & Amortization | $28K+94.6% | $28K-29.3% | $28K-33.9% | $29K-40.9% | $14K-54.2% | $40K+35.3% | $43K+45.1% | $49K-30.7% |
| Capital Expenditures | $250-98.8% | $325-96.4% | $977-75.7% | $5K-97.2% | $21K+1070.7% | $9K-58.8% | $4K+329.2% | $199K+48.6% |
| Free Cash Flow | -$423Kn/m | -$148Kn/m | $960K+346.2% | -$1.2Mn/m | -$759Kn/m | -$833Kn/m | $215Kn/m | -$1.8Mn/m |
| Investing Cash Flow | $416Kn/m | -$14Kn/m | -$6K-101.0% | $995Kn/m | -$29K-145.1% | -$16K-528.7% | $554Kn/m | -$203Kn/m |
| Financing Cash Flow | $14Kn/m | $60Kn/m | $267Kn/m | $34Kn/m | -$1K-100.6% | -$860-103.2% | -$142K-126.8% | -$56K-101.0% |
Not reported in any period shown, so not listed: Stock-Based Compensation, Dividends Paid, Share Buybacks.
BGLC Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 17.1%+0.8pp | -3.5%-19.5pp | -0.8%-13.1pp | 14.8%+2.4pp | 16.3%+1.7pp | 16.1%+0.7pp | 12.3%+0.5pp | 12.4%-1.5pp |
| Operating Margin | -370.8% | -2366.2% | -213.5% | -27.6%+23.2pp | -27.1%-40.2pp | -28.9%-25.6pp | -16.5%-27.8pp | -50.8%+48.2pp |
| Net Margin | -376.1% | -2379.7% | -214.2% | -27.9%+23.3pp | -27.3%-37.3pp | -29.2%-24.8pp | -13.8%-27.4pp | -51.1% |
| Return on Equity | -3.7%+4.5pp | -6.7%+1.3pp | -12.0%-7.8pp | -10.4%+3.9pp | -8.2%-10.3pp | -8.0%-6.9pp | -4.2%-7.4pp | -14.3%+13.7pp |
| Return on Assets | -3.3%+3.3pp | -6.0%+0.6pp | -11.2%-7.9pp | -9.3%+2.9pp | -6.5%-8.3pp | -6.6%-5.6pp | -3.3%-6.0pp | -12.2%+10.5pp |
| Current Ratio | 6.08+2.5x | 6.52+2.3x | 10.46+6.7x | 8.30+3.3x | 3.63-2.0x | 4.19-0.4x | 3.81-1.1x | 4.98-0.1x |
| Liabilities-to-Equity | 0.12-0.1x | 0.12-0.1x | 0.07-0.2x | 0.12-0.1x | 0.25+0.1x | 0.220.0x | 0.25+0.1x | 0.170.0x |
| Asset Turnover | 0.01-0.2x | 0.00-0.2x | 0.05-0.2x | 0.33+0.1x | 0.24+0.1x | 0.230.0x | 0.240.0x | 0.240.0x |
| FCF Margin | -555.1% | -647.9% | 198.5% | -48.9%+19.7pp | -33.6%+0.5pp | -39.0%-36.5pp | 8.5%+43.0pp | -68.5%-28.1pp |
Not reported in any period shown, so not listed: Debt-to-Equity.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| BioNexus Gene Lab Corp BGLC | FY2025 | $7.4M | -$3.0M | -40.2% | $3.5M | 43/100 |
| CN Energy Group Inc. CNEY | FY2025 | $35.6M | -$11.1M | -31.3% | $2.6M | 53/100 |
| BOLT PROJECTS HLDGS INC BSLK | FY2024 | $1.4M | N/A | N/A | N/A | — |
| Bon Natural Life Limited BON | FY2025 | $18.7M | -$2.0M | -10.7% | $9.4M | 38/100 |
| SenesTech, Inc. SNES | FY2025 | $2.2M | -$6.4M | N/A | $4.2M | 63/100 |
| Northern Technologies International Corp. NTIC | FY2025 | $84.2M | $18K | 0.0% | $72.6M | 51/100 |
Where BioNexus Gene Lab Corp Ranks
Frequently Asked Questions
What is BioNexus Gene Lab Corp's annual revenue?
BioNexus Gene Lab Corp (BGLC) reported $7.4M in total revenue for fiscal year 2025. This represents a -21.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is BioNexus Gene Lab Corp's revenue growing?
BioNexus Gene Lab Corp (BGLC) revenue declined by 21.9% year-over-year, from $9.5M to $7.4M in fiscal year 2025.
Is BioNexus Gene Lab Corp profitable?
No, BioNexus Gene Lab Corp (BGLC) reported a net loss of $2.6M over the trailing 12 months to June 30, 2026. In fiscal year 2025 it reported a net loss of $3.0M, with a net profit margin of -40.2%.
What is BioNexus Gene Lab Corp's EBITDA?
BioNexus Gene Lab Corp (BGLC) had EBITDA of -$2.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is BioNexus Gene Lab Corp's gross margin?
BioNexus Gene Lab Corp (BGLC) had a gross margin of 14.6% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is BioNexus Gene Lab Corp's operating margin?
BioNexus Gene Lab Corp (BGLC) had an operating margin of -39.9% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is BioNexus Gene Lab Corp's net profit margin?
BioNexus Gene Lab Corp (BGLC) had a net profit margin of -40.2% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is BioNexus Gene Lab Corp's return on equity (ROE)?
BioNexus Gene Lab Corp (BGLC) has a return on equity of -34.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is BioNexus Gene Lab Corp's free cash flow?
BioNexus Gene Lab Corp (BGLC) recorded an outflow of $1.9M in free cash flow during fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is BioNexus Gene Lab Corp's operating cash flow?
BioNexus Gene Lab Corp (BGLC) recorded an outflow of $1.8M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are BioNexus Gene Lab Corp's total assets?
BioNexus Gene Lab Corp (BGLC) had $9.3M in total assets as of fiscal year 2025, including both current and long-term assets.
What are BioNexus Gene Lab Corp's capital expenditures?
BioNexus Gene Lab Corp (BGLC) invested $37K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does BioNexus Gene Lab Corp spend on research and development?
BioNexus Gene Lab Corp (BGLC) invested $51K in research and development during fiscal year 2025.
What is BioNexus Gene Lab Corp's current ratio?
BioNexus Gene Lab Corp (BGLC) had a current ratio of 10.46 as of fiscal year 2025, which is generally considered healthy.
What is BioNexus Gene Lab Corp's liabilities-to-equity ratio?
BioNexus Gene Lab Corp (BGLC) had a liabilities-to-equity ratio of 0.07 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2025, because the filing data we hold for that year carries no long-term debt figure.
What is BioNexus Gene Lab Corp's return on assets (ROA)?
BioNexus Gene Lab Corp (BGLC) had a return on assets of -32.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is BioNexus Gene Lab Corp's P/E ratio?
BioNexus Gene Lab Corp (BGLC) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to June 30, 2026). The market capitalization is $3.5M as of Oct 22, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is BioNexus Gene Lab Corp's price-to-sales ratio?
BioNexus Gene Lab Corp (BGLC) trades at 1.1x sales, its market capitalization divided by $3.1M revenue, trailing 12 months to June 30, 2026. The market capitalization is $3.5M as of Oct 22, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is BioNexus Gene Lab Corp's Altman Z-Score?
BioNexus Gene Lab Corp (BGLC) has an Altman Z-Score of 2.70, placing it in the Grey Zone (moderate risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is BioNexus Gene Lab Corp's Piotroski F-Score?
BioNexus Gene Lab Corp (BGLC) has a Piotroski F-Score of 4 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are BioNexus Gene Lab Corp's earnings high quality?
BioNexus Gene Lab Corp (BGLC) reported a net loss of $3.0M while operations used $1.8M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is BioNexus Gene Lab Corp?
BioNexus Gene Lab Corp (BGLC) scores 43 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is the average of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. For BioNexus Gene Lab Corp it averages the 4 of 6 dimensions that can be computed; the others are left out rather than counted as zero. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.